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adds cost, which must be documented by improved out-
comes. This is not always the case as the recent metal/
metal data has shown. The current economics of arthro-
plasty surgery have put increasing financial pressure on
hospitals and will progress under new healthcare legisla-
tion. New technology must be cost-effective, and this will
be increasingly difficult in an era of outstanding long-term
results with current designs. Cost may necessitate less
expensive alternatives (e.g., generic implants) in arthro-
plasty patients.
Joint replacement surgery has evolved over the past four
decades into a highly successful surgical procedure. Earlierticle is a summary of a talk
l meeting of the Hong Kong
07.002
hor. Published by Elsevier (Singap
licenses/by-nc-nd/4.0/).designs and materials which demonstrated inferior func-
tional and long-term results have disappeared in a
Darwinian fashion. Through this evolutionary process, many
of the current designs have proven efficacy and durability.
Current outcome data indicates that hip and knee designs
demonstrate 90e95% success rates at 15 years follow-up
[1]. Technological advances are necessary to improve
implant design and materials; however, only in an envi-
ronment of reduced reimbursement to hospitals can the
increased cost be justified.
The rationale that technology in medicine would be
expensive at the outset yet be cost-effective eventually has
not been the case in many areas. Currently, about one half
of the rapid increase in healthcare costs in relation to Gross
National Product may be attributed to technology. Uwe
Reinhardt, an economist at Princeton University, in refer-
ring to new technology has stated that the healthcare sys-
tem provides misaligned incentives that create over-
utilisation or misutilisation of everything that is new. It isore) Pte Ltd. This is an open access article under the CC BY-NC-ND
20 T.P. Sculconow common knowledge among healthcare economists that
if the cost of healthcare is to be controlled, the growth of
technology must be constrained.
Increasingly, as new technology emerges, the question
will be: What is the costebenefit analysis? A new era of
comparative effectiveness research is being launched and
will become predominant in medicine and arthroplasty sur-
gery in the future. What is the newest may not always be the
best. According to Reinhardt, there is a need for comparative
effectiveness studies of emerging and existing technology so
that the new can be priced in a way that reflects its incre-
mental value. New technology must demonstrate its benefit
to justify its cost; often in arthroplasty, there is little data
available to document these better outcomes.
The high flex knee designs are an example of implant
modification adding significant cost to the prosthesis. This
design is intended to provide greater knee motion for pa-
tients; however, there are many patient-related variables
which impact on knee motion, and there is little substan-
tiated evidence that these implants produce knee flexion
that is superior to conventional designs. The gender-
specific knee design, despite increased cost, has not pro-
duced better outcomes.
In terms of computer-assisted surgery, this is a tech-
nology that has struggled to gain a foothold in arthroplasty
surgery. Computer-assisted navigation for joint replace-
ment adds cost to the procedure both in terms of equip-
ment and added operating time. If these systems,
particularly in hip replacement surgery, improve acetabular
orientation and leg length equality, then the cost may be
justified; however, this has not been demonstrated to date.
Additionally, current systems require multiple pin insertion
for tracking devices which may increase morbidity. Navi-
gation system cost must be reduced and the tracking
mechanisms must be simplified to justify generalised uti-
lisation. A recent paper by Kim et al. [2]. reports results in
520 bilateral total knee replacements, one side performed
with navigation, and one side with conventional instru-
mentation. At 10.8 years mean follow-up, there was no
difference in “clinical function or alignment and survivor-
ship of the components” between the two techniques.
Robotic surgery is another example of expensive tech-
nology with little evidenced-based literature to support its
use. Robotic systems can cost from $750,000 and currently
add time to the procedure.
If we look to the future, there will certainly be a place
for these navigation-assisted surgical devices, and the
technology will improve and be more cost-effective and
user-friendly. In the end, it may improve the accuracy in
low volume surgeons and reduce outlier implant results.
Implant costs can account for 30e40% of hospital costs
for a joint replacement patient, and new bearing surfaces
and designs always come with significant increase in price.
Only minor changes in design will generate cost increase of
up to 25% without evidence of improved outcome. With
current healthcare reform policy, reimbursement to hos-
pitals will continue to decline and cost of new technology
will not be sustainable in most hospitals with current profit
margins of 1e2%. Large implant manufacturers havedocumented profit margins in the order of 15e25%, and
reduction in implant costs with or without new technologies
must occur for many hospitals to survive. If indeed the
implant industry is able to do this, then there may be a
place for their utilisation in younger patients with greater
life expectancy.
In a recent study by Bozic et al. [3], the cost-
effectiveness of new technologies were evaluated. Based
on the authors’ findings for an alternative bearing with an
incremental cost of $2000 to be cost saving for a 50-year-
old, there would have to be a 19% reduction in 20-year
failure rates. The likelihood of cost savings for these al-
ternate bearings in patients 63 years or older is highly un-
likely at current costs. Newer biomaterials (metal/metal,
ceramic/ceramic, highly cross linked polyethylene) also
have limited outcome analysis in patients beyond short- to
mid-term follow-up evaluation, and all of these technolo-
gies add significant cost to the implant. Metal-on-metal hip
arthroplasty has had significant issues with severe peri-
prosthetic reaction with necrosis and, in some cases,
pseudotumour formation. With diminishing reimbursement,
careful analysis of utilisation of these newer technologies
must be weighed if hospitals are to maintain economic
viability.
The pharmaceutical, airline, and food industries have all
moved towards generic products which are less costly, and
this will be the trend in the future in prosthetic implants as
well. Newer technologies must demonstrate their efficacy
in long-term follow-up and be clearly superior to conven-
tional implants. Examples such as modular femoral neck
designs, metal-on-metal articulations, and newer designs
with increased impingement are demonstrating early fail-
ure results inferior to earlier proven designs and materials.
Change does not always mean progress.References
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